Heart Failure | Unmet Need | Chronic Heart Failure | US/EU | 2016
Despite advances in treatment, rates of mortality and hospitalization for worsening heart failure remain high among CHF patients, and development of therapies with improved efficacy is one of the greatest unmet needs. Furthermore, given that none of the currently available CHF treatments has proven outcome benefits in HFpEF patients, who constitute approximately 50% of CHF cases, a significant unmet need lies with this patient population. Therefore, significant clinical and commercial opportunities persist for therapies that can improve outcomes in this heterogeneous patient population.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
